Kinase domain mutations in cancer: Implications for small molecule drug design strategies

Journal of Medicinal Chemistry

Volumn 52, Issue 6, 2009, Pages 1493-1509

  Bikker, Jack A ^a   Brooijmans, Natasja ^a   Wissner, Allan ^a   Mansour, Tarek S ^a  

^a WYETH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [2 METHOXY 5 (2,4,6 TRIMETHOXYSTYRYLSULFONYLMETHYL)ANILINO]PROPIONIC ACID; 6 (2,6 DICHLOROPHENYL) 2 (4 FLUORO 3 METHYLANILINO) 8 METHYL 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; [4 [2 CYCLOPENTYL 9 (3 HYDROXYPHENETHYL)PURIN 6 YLAMINO]PHENYL]DIMETHYLPHOSPHINE OXIDE; AP 23846; BCR ABL PROTEIN; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; IMATINIB; LAPATINIB; MUTANT PROTEIN; NILOTINIB; PHOSPHOTRANSFERASE; PHOSPHOTRANSFERASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR; SORAFENIB; STEM CELL FACTOR; SUNITINIB; UNCLASSIFIED DRUG;

BREAST CANCER; CATALYSIS; CHRONIC MYELOID LEUKEMIA; CRYSTALLOGRAPHY; DRUG BINDING; DRUG EFFICACY; DRUG INHIBITION; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME STRUCTURE; GENE MUTATION; HUMAN; HYDROPHOBICITY; LUNG NON SMALL CELL CANCER; PROTEIN DOMAIN; PROTEIN MOTIF; REVIEW;

AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASMS; PHOSPHOTRANSFERASES; PROTEIN CONFORMATION;

EID: 64349099558     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm8010542     Document Type: Review

References (115)

1. Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S. The protein kinase complement of the human genome. Science 2002, 298 (5600), 1912-1934.
2. LaRusso, P. M.; Eder, J. P. Therapeutic potential of novel selective- spectrum kinase inhibitors in oncology. Expert Opin. Invest. Drugs 2008, 17 (7), 1013-1028.
3. Liao, J. J.-L. Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. J. Med. Chem. 2007, 50 (3), 409-424.
4. Liao, J. J.-L.; Andrews, R. C. Targeting protein multiple conformations: a structure-based strategy for kinase drug design. Curr. Top. Med. Chem. 2007, 7, 1394-1407.
5. Carter, T. A.; Dodicka, L. M.; Shah, N. P.; Velasco, A. M.; Fabian, M. A.; Treiber, D. K.; Milanov, Z. V.; Atteridge, C. E.; Biggs, W. H.; Edeen, P. T.; Floyd, M.; Ford, J.; Grotzfeld, R. M.; Herrfard, S.; Insko, D. E.; Mehta, S. A.; Paetel, H. K.; Pao, W.; Sawyers, C. L.; Varmus, H.; Zarinkar, P. P.; Lockhart, D. J. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc. Natl. Acad. Sci. U.S.A. 2005, 102 (31), 11011-11016.
6. Daub, H.; Specht, K.; Ullrich, A. Strategies to overcome resistance to targeted protein kinase inhibitors. Nat. Rev. Drug Discovery 2004, 3 (12), 1001-1010.
7. Kobayashi, S.; Boggon, T. J.; Dayaram, T.; Janne, P.; Kocher, O.; Meyerson, M.; Johnson, B. E.; Eck, M. J.; Tenen, D. G.; Halmos, B. EGFR mutation and resitance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2005, 352 (8), 786-792.
8. Dowell, J. E.; Minna, J. D. Chasing mutations in the epidermal growth factor in lung cancer. N. Engl. J. Med. 2005, 352 (8), 830-832.
9. Gorre, M. E.; Mohammed, M.; Ellwood, K.; Hsu, N.; Paquette, R. L.; Rao, P. N.; Sawyers, C. L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293, 876-880.
10. Engelman, J. A.; Zejnullahu, K.; Misudomi, T.; Song, Y.; Hyland, C.; Park, J. O.; Lindeman, N.; Gale, C.-M.; Zhao, X.; Christensen, J.; Kosaka, T.; Holmes, A., J; Rogers, A. M.; Cappuzzo, F.; Mok, T.; Lee, C.; Johnson, B. E.; Cantley, L. C.; Janne, P. A. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316 (5827), 1039-1043.
11. Quintas-Cardama, A.; Cortes, J. Therapeutic options against BCR- ABL1 T315I-positive chronic myelogenous leukemia. Clin. Cancer Res. 2008, 14 (14), 4392-4399.
12. Druker, B. J.; Tamaru, S.; Buchdunger, E.; Ohno, S.; Segal, G. M.; Zimmermann, J.; Lydon, N. B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 1996, 2, 561-566.
13. Boschelli, D. H. Bcr-Abl kinase inhibitors. Top. Med. Chem. 2007, 1, 407-444.
14. Noronha, G.; Cao, J.; Chow, C. P.; Dneprovskaia, E.; Fine, R. M.; Hood, J.; Kang, X.; Klebansky, B.; Lohse, D.; Mak, C. C.; McPherson, A.; Moorthy, S. S. P.; Pathak, V. P.; Renick, J.; Soll, R.; Zeng, B. Inhibitors of ABL and the ABL-T315I mutation. Curr. Top. Med. Chem. 2008, 8, 905-921.
15. Quintas-Cardama, A.; Kantarijian, H.; Cortes, J. Flying under the radar: the new wave of BCR-ABL inhibitors. Nat. Rev. Drug Discovery 2007, 6 (10), 834-848.
16. Chan, S. K.; Gullick, W. J.; Hill, M. E. Mutations of the epidermal growth factor receptor in non-small cell lung cancer-search and destroy. Eur. J. Cancer 2006, 42, 17-23.
17. Gazdar, A. F.; Shigematsu, H.; Herz, J.; Minna, J. D. Mutations and addiction to EGFR: the Achilles "heal" of lung cancers. Trends Mol. Med. 2004, 10 (10), 481-486.
18. Ji, H.; Zhao, X.; Yuza, Y.; Shimamura, T.; Li, D.; Protopopov, A.; Jung, B. L.; McNamara, K.; Xia, H.; Glatt, K. A.; Thomas, R. K.; Sasaki, H.; Horner, J. W.; Eck, M. J.; Discafani, C. M.; Maher, E.; Shapiro, G. I.; Meyerson, M.; Wong, K.-K. Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc. Natl. Acad. Sci. U.S.A. 2006, 103 (20), 7817-7822.
19. Johnson, B. E.; Janne, P. Epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Cancer Res. 2005, 65 (17), 7525-7529.
20. Lynch, T. J.; Bell, D. W.; Sordella, R.; Gurubhagavatual, S.; Okimoto, R. A.; Brannigan, B. W.; Harris, P. L.; Haserlat, S. M.; Supko, J. G.; Haluska, F. G.; Louis, D. N.; Christiani, D. C.; Settleman, J.; Haber, D. A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350 (21), 2129-2139.
21. Paez, J. G.; Janne, P. A.; Lee, J. C.; Tracy, S.; Greulich, H.; Gabriel, S.; Herman, P.; Kaye, F. J.; Lindeman, N.; Boggon, T. J.; Naoki, K.; Sasaki, H.; Fujii, Y.; Eck, M. J.; Sellers, W. R.; Johnson, B. E.; Meyerson, M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304, 1497-1500.
22. Pao, W.; Miller, V. A.; Politi, K. A.; Reily, G. I.; Somwar, R.; Zakowski, M. F. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 13306-13311.
23. Faivre, S.; Demetri, G.; Sargent, W.; Raymond, E. Molecular basis for sunitinib efficacy and future clinical development. Nat. Rev. Drug Discovery 2007, 6 (9), 734-745.
24. Sun, L.; Liang, C.; Shirazian, S.; Zhou, T.; Miller, T.; Cui, J.; Fukuda, J. Y.; Chu, J.-Y.; Nematalla, A.; Wang, X.; Chen, H.; Wei, J.; Tang, C. Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenem-ethyl]-2,4- dimethyl-1 H-pyrrole-3-carboxylic acid (2-diethylamino- ethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J. Med. Chem. 2003, 46 (7), 1116-1119.
25. Lowinger, T.; Riedl, B.; Dumas, J.; Smith, R. A. Design and discovery of small molecules targeting Raf-1 kinase. Curr. Pharm. Des. 2002, 8 (25), 2269-2278.
26. Huse, M.; Kuriyan, J. The conformational plasticity of protein kinases. Cell 2002, 109 (3), 275-282.
27. Liu, Y.; Gray, N. S. Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol. 2006, 2 (7), 358-364.
28. Masterson, L. R.; Mascioni, A.; Traaseth, N. J.; Taylor, S. S.; Veglia, G. Allosteric cooperativity in protein kinase A. Proc. Natl. Acad. Sci. U.S.A. 2008, 105 (2), 506-511.
29. Vajpai, N.; Strauss, A.; Fendrich, G.; Cowan-Jacob, S. W.; Manley, P. W.; Grzesiek, S.; Jahnke, W. Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib. J. Biol. Chem. 2008, 283 (26), 18292-18302.
30. Dorsey, J. F.; Jove, R.; Kraker, A. J.; Wu, J. The pyrido[2,3-d] pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells. Cancer Res. 2000, 60 (12), 3127-3131.
31. Kraker, A. J.; Hartl, B. G.; Amar, A. M.; Barvian, M. R.; Showalter, H. D. H.; Moore, C. W. Biochemical and cellular effects of c-Src kinase-selective pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. Biochem. Pharmacol. 2000, 60 (7), 885-898.
32. Wood, E. R.; Tuesdale, A. T.; McDonald, O. B.; Yan, D.; Hassell, A.; Dickerson, S. H.; Ellis, B.; Pennisi, C.; Horne, E.; Lakcey, K.; Alligood, K. J.; Rusnak, D. W.; Gilbmer, T. M.; Shewchuck, L. A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 2004, 64, 66452-66659.
33. Yun, C.-H.; Mengwasser, K. E.; Toms, A. V.; Woo, M. S.; Greulich, H.; Wong, K.-K.; Meyerson, M.; Eck, M. J. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 2070-2075.
34. Zhang, X.; Gureasko, J.; Shen, H.; Cole, P. A.; Kuriyan, J. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 2006, 125, 1137-1149.
35. Zhang, X.; Pickin, K. A.; Bose, R.; Jura, N.; Cole, P. A.; Kuriyan, J. Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. Nature 2007, 450, 741-745.
36. Levinson, N. M.; Kuchment, O.; Shen, K.; Young, M. A.; Koldobskiy, M.; Karplus, M.; Cole, P. A.; Kuriyan, J. A Src-like inactive conformation in the Abl tyrosine kinase domain. PLoS Biol. 2006, 4 (5), 753-767.
37. Seeliger, M. A.; Nagar, B.; Frank, F.; Coa, X.; Henderson, M. N.; Kuriyan, J. c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty. Structure 2007, 15, 299-311.
38. Ji, H.; Li, D.; Chen, L.; Shimamura, T.; Kobayahshi, S.; McNamara, K.; Mahmood, U.; Mitchell, A.; Sun, Y.; Al-Hashem, R.; Chirieac, L. R.; Padera, R.; Bronson, R. T.; Kim, W.; Janne, P.; Shapiro, G. I.; Tenen, D. G.; Johnson, B. E.; Weissleder, R.; Sharpless, N. E.; Wong, K.-K. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 2006, 9, 485-495.
39. Modugno, M.; Casale, E.; Soncini, C.; Rosettani, P.; Colombo, R.; Lupi, R.; Rusconi, L.; Fancelli, D.; Carpinelli, P.; Cameron, A. D.; Isacchi, A.; Moll, J. Crystal structure of the T315I Abl mutant in complex with the Aurora kinase inhibitor PHA-739358. Cancer Res. 2007, 67 (17), 7987-7990.
40. Young, M. A.; Shah, N. P.; Chao, L. H.; Seeliger, M.; Milanov, Z. V.; Biggs, W. H., 3rd; Treiber, D. K.; Patel, H. K.; Zarrinkar, P. P.; Lockhart, D. J.; Sawyers, C. L.; Kuriyan, J. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res. 2006, 66 (2), 1007-1014.
41. Zhou, T.; Parillon, L.; Li, F.; Wang, Y.; Keats, J.; Lamore, S.; Xu, Q.; Shakespeare, W.; Dalgarno, D.; Zhu, X. Crystal structure of the T315I mutant of Abl kinase. Chem. Biol. Drug Des. 2007, 70 (3), 171-181.
42. Yun, C.-H.; Boggon, T. J.; Li, Y.; Woo, M. S.; Greulich, H.; Meyerson, M.; Eck, M. J. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 2007, 11, 217-227.
43. Beghini, A.; Cairoli, R.; Morra, E.; Larizza, L. In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent C-kit mutation. Blood Cells, Mol. Dis. 1998, 24 (2), 262270.
44. Chompret, A.; Kannengiesser, C.; Barrois, M.; Terrier, P.; Dahan, P.; Tursz, T.; Lenoir, G. M.; Bressac-De Paillerets, B. PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor. Gastroenterology 2004, 126 (1), 318-321.
45. Heinrich, M. C.; Corless, C. L.; Duensing, A.; McGreevey, L.; Chen, C. J.; Joseph, N.; Singer, S.; Griffith, D. J.; Haley, A.; Town, A.; Demetri, G. D.; Fletcher, C. D.; Fletcher, J. A. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003, 299 (5607), 708-710.
46. Azam, M.; Nardi, V.; Shakespeare, W. C.; Metcalf, C. A., III; Bohacek, R. S.; Wang, Y.; Sundaramoorthi, R.; Sliz, P.; Veach, D. R.; Bornmann, W. G.; Clarkson, B.; Dalgarno, D. C.; Sawyer, T. K.; Daley, G. Q. Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance. Proc. Natl. Acad. Sci. U.S.A. 2006, 103 (24), 9244-9249.
47. Hochhaus, A.; Kreil, S.; Corbin, A. S.; La Rosee, P.; Muller, M. C.; Lahaye, T.; Hanfstein, B.; Schoch, C.; Cross, N. C.; Berger, U.; Gschaidmeier, H.; Druker, B. J.; Hehlmann, R. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002, 16 (11), 2190-2196.
48. Roumiantsev, S.; Shah, N. P.; Gorre, M. E.; Nicoll, J.; Brasher, B. B.; Sawyers, C. L.; Van Etten, R. A. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc. Natl. Acad. Sci. U.S.A. 2002, 99 (16), 10700-10705.
49. Shah, N. P.; Nicoll, J. M.; Nagar, B.; Gorre, M. E.; Paquette, R. L.; Kuriyan, J.; Sawyers, C. L. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002, 2 (2), 117-125. [Comment].
50. O'Hare, T.; Eide, C. A.; Deininger, M. W. Bcr-Abl kinase domain mutations and the unsettled problem of Bcr-AblT315I: looking into the future of controlling drug resistance in chronic myeloid leukemia. Clin. Lymphoma Myeloma 2007, 7 (Suppl. 3), S120-S130.
51. Soverini, S.; Colarossi, S.; Gnani, A.; Rosti, G.; Castagnetti, F.; Poerio, A.; Iacobucci, I.; Amabile, M.; Abruzzese, E.; Orlandi, E.; Radaelli, F.; Ciccone, F.; Tiribelli, M.; di Lorenzo, R.; Caracciolo, C.; Izzo, B.; Pane, F.; Saglio, G.; Baccarani, M.; Martinelli, G.; Leukemia, G. W. P. o. C. M. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin. Cancer Res. 2006, 12 (24), 7374-7379.
52. Nagar, B.; Bornmann, W. G.; Pellicena, P.; Schindler, T.; Veach, D. R.; Miller, W. T.; Clarkson, B.; Kuriyan, J. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 2002, 62 (15), 4236-4243.
53. Azam, M.; Seeliger, M. A.; Gray, N. S.; Kuriyan, J.; Daley, G. Q. Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat. Struct. Mol. Biol. 2008, 15 (10), 1109-1118.
54. Kornev, A. P.; Haste, N. M.; Taylor, S. S.; Eyck, L. F. Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 17783-17788.
55. Friesner, R. A.; Murphy, R. B.; Repasky, M. P.; Frye, L. L.; Greenwood, J. R.; Halgren, T. A.; Sanschagrin, P. C.; Mainz, D. T. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J. Med. Chem. 2006, 49 (21), 6177-6196.
56. Carter, T. A.; Wodicka, L. M.; Shah, N. P.; Velasco, A. M.; Fabian, M. A.; Treiber, D. K.; Milanov, Z. V.; Atteridge, C. E.; Biggs, W. H.; Edeen, P. T.; Floyd, M.; Ford, J. M.; Grotzfeld, R. M.; Herrgard, S.; Insko, D. E.; Mehta, S. A.; Patel, H. K.; Pao, W.; Sawyers, C. L.; Varmus, H.; Zarrinkar, P. P.; Lockhart, D. J. Inhibition of drug- resistant mutants of ABL, KIT, and EGF receptor kinases. Proc. Natl. Acad. Sci. U.S.A. 2005, 102 (31), 11011-11016.
57. O'Hare, T.; Walters, D. K.; Stoffregen, E. P.; Jia, T.; Manley, P. W.; Mestan, J.; Cowan-Jacob, S. W.; Lee, F. Y.; Heinrich, M. C.; Deininger, M. W.; Druker, B. J. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005, 65 (11), 4500-4505.
58. le Coutre, P.; Ottmann, O. G.; Giles, F.; Kim, D.-W.; Cortes, J.; Gattermann, N.; Apperley, J. F.; Larson, R. A.; Abruzzese, E.; O'Brien, S. G.; Kuliczkowski, K.; Hochhaus, A.; Mahon, F.-X.; Saglio, G.; Gobbi, M.; Kwong, Y.-L.; Baccarani, M.; Hughes, T.; Martinelli, G.; Radich, J. P.; Zheng, M.; Shou, Y.; Kantarjian, H. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or-intolerant accelerated-phase chronic myelogenous leukemia. Blood 2008, 111 (4), 1834-1839.
59. O'Hare, T.; Eide, C. A.; Tyner, J. W.; Corbin, A. S.; Wong, M. J.; Buchanan, S.; Holme, K.; Jessen, K. A.; Tang, C.; Lewis, H. A.; Romero, R. D.; Burley, S. K.; Deininger, M. W. SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib. Proc. Natl. Acad. Sci. U.S.A. 2008, 105 (14), 5507-5512.
60. Harrington, E. A.; Bebbington, D.; Moore, J.; Rasmussen, R. K.; Ajose-Adeogun, A. O.; Nakayama, T.; Graham, J. A.; Demur, C.; Hercend, T.; Diu-Hercend, A.; Su, M.; Golec, J. M. C.; Miller, K. M. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat. Med. 2004, 10 (3), 262-267.
61. Shah, N. P.; Skaggs, B. J.; Branford, S.; Hughes, T. P.; Nicoll, J. M.; Paquette, R. L.; Sawyers, C. L. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J. Clin. Invest. 2007, 117 (9), 2562-2569.
62. Giles, F. J.; Cortes, J.; Jones, D.; Bergstrom, D.; Kantarjian, H.; Freedman, S. J. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 2007, 109 (2), 500-502.
63. Gumireddy, K.; Baker, S. J.; Cosenza, S. C.; John, P.; Kang, A. D.; Robell, K. A.; Reddy, M. V. R.; Reddy, E. P. A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc. Natl. Acad. Sci. U.S.A. 2005, 102 (6), 1992-1997.
64. Miettinen, M.; Sarlomo-Rikala, M.; Lasota, J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum. Pathol. 1999, 30 (10), 1213-1220.
65. Hirota, S.; Isozaki, K.; Moriyama, Y.; Hashimoto, K.; Nishida, T.; Ishiguro, S.; Kawano, K.; Hanada, M.; Kurata, A.; Takeda, M.; Muhammad Tunio, G.; Matsuzawa, Y.; Kanakura, Y.; Shinomura, Y.; Kitamura, Y. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998, 279 (5350), 577-580.
66. Joensuu, H.; Roberts, P. J.; Sarlomo-Rikala, M.; Andersson, L. C.; Tervahartiala, P.; Tuveson, D.; Silberman, S. L.; Capdeville, R.; Dimitrijevic, S.; Druker, B.; Demetri, G. D. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med. 2001, 344 (14), 1052-1056.
67. Verweij, J.; Casali, P. G.; Zalcberg, J.; LeCesne, A.; Reichardt, P.; Blay, J.-Y.; Issels, R.; van Oosterom, A.; Hogendoorn, P. C. W.; Van Glabbeke, M.; Bertulli, R.; Judson, I. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004, 364 (9440), 1127-1134.
68. Demetri, G. D.; von Mehren, M.; Blanke, C. D.; Van den Abbeele, A. D.; Eisenberg, B.; Roberts, P. J.; Heinrich, M. C.; Tuveson, D. A.; Singer, S.; Janicek, M.; Fletcher, J. A.; Silverman, S. G.; Silberman, S. L.; Capdeville, R.; Kiese, B.; Peng, B.; Dimitrijevic, S.; Druker, B. J.; Corless, C.; Fletcher, C. D.; Joensuu, H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 2002, 347 (7), 472-480. [see Comment].
69. Mol, C. D.; Dougan, D. R.; Schneider, T. R.; Skene, R. J.; Kraus, M. L.; Scheibe, D. N.; Snell, G. P.; Zou, H.; Sang, B.-C.; Wilson, K. P. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J. Biol. Chem. 2004, 279 (30), 31655-31663.
70. Antonescu, C. R.; Besmer, P.; Guo, T.; Arkun, K.; Hom, G.; Koryotowski, B.; Leversha, M. A.; Jeffrey, P. D.; Desantis, D.; Singer, S.; Brennan, M. F.; Maki, R. G.; DeMatteo, R. P. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin. Cancer Res. 2005, 11 (11), 4182-4190.
71. Chen, L. L.; Trent, J. C.; Wu, E. F.; Fuller, G. N.; Ramdas, L.; Zhang, W.; Raymond, A. K.; Prieto, V. G.; Oyedeji, C. O.; Hunt, K. K.; Pollock, R. E.; Feig, B. W.; Hayes, K. J.; Choi, H.; Macapinlac, H. A.; Hittelman, W.; Velasco, M. A.; Patel, S.; Burgess, M. A.; Benjamin, R. S.; Frazier, M. L. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res. 2004, 64 (17), 5913-5919.
72. Nishida, T.; Kanda, T.; Nishitani, A.; Takahashi, T.; Nakajima, K.; Ishikawa, T.; Hirota, S. Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib-resistant gastrointestinal stromal tumor. Cancer Sci. 2008, 99 (4), 799-804.
73. Wardelmann, E.; Thomas, N.; Merkelbach-Bruse, S.; Pauls, K.; Speidel, N.; Buttner, R.; Bihl, H.; Leutner, C. C.; Heinicke, T.; Hohenberger, P. Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. Lancet Oncol. 2005, 6 (4), 249-251.
74. Bickenbach, K.; Wilcox, R.; Veerapong, J.; Kindler, H. L.; Posner, M. C.; Noffsinger, A.; Roggin, K. K. A review of resistance patterns and phenotypic changes in gastrointestinal stromal tumors following imatinib mesylate therapy. J. Gastrointest. Surg. 2007, 11 (6), 758-766.
75. Guo, T.; Agaram, N. P.; Wong, G. C.; Hom, G.; D'Adamo, D.; Maki, R. G.; Schwartz, G. K.; Veach, D.; Clarkson, B. D.; Singer, S.; DeMatteo, R. P.; Besmer, P.; Antonescu, C. R. Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Clin. Cancer Res. 2007, 13 (16), 4874-4881.
76. Nagata, H.; Worobec, A. S.; Oh, C. K.; Chowdhury, B. A.; Tannenbaum, S.; Suzuki, Y.; Metcalfe, D. D. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc. Natl. Acad. Sci. U.S.A. 1995, 92 (23), 10560-10564.
77. Druker, B. J.; Tamura, S.; Buchdunger, E.; Ohno, S.; Segal, G. M.; Fanning, S.; Zimmermann, J.; Lydon, N. B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 1996, 2 (5), 561-566.
78. Buchdunger, E.; Cioffi, C. L.; Law, N.; Stover, D.; Ohno-Jones, S.; Druker, B. J.; Lydon, N. B. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther. 2000, 295 (1), 139-145.
79. Shimizu, A.; O'Brien, K. P.; Sjoblom, T.; Pietras, K.; Buchdunger, E.; Collins, V. P.; Heldin, C.-H.; Dumanski, J. P.; Ostman, A. The dermatofibrosarcoma protuberans-associated collagen type Ia1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res. 1999, 59 (15), 3719-3723.
80. Simon, M. P.; Pedeutour, F.; Sirvent, N.; Grosgeorge, J.; Minoletti, F.; Coindre, J. M.; Terrier-Lacombe, M. J.; Mandahl, N.; Craver, R. D.; Blin, N.; Sozzi, G.; Turc-Carel, C.; O'Brien, K. P.; Kedra, D.; Fransson, I.; Guilbaud, C.; Dumanski, J. P. Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nat. Genet. 1997, 15 (1), 95-98.
81. Sjoblom, T.; Boureux, A.; Ronnstrand, L.; Heldin, C. H.; Ghysdael, J.; Ostman, A. Characterization of the chronic myelomonocytic leukemia associated TEL-PDGF beta R fusion protein. Oncogene 1999, 18 (50), 7055-7062.
82. Jousset, C.; Carron, C.; Boureux, A.; Quang, C. T.; Oury, C.; Dusanter-Fourt, I.; Charon, M.; Levin, J.; Bernard, O.; Ghysdael, J. A domain of TEL conserved in a subset of ETS proteins defines a specific oligomerization interface essential to the mitogenic properties of the TEL-PDGFR beta oncoprotein. EMBO J. 1997, 16 (1), 69-82.
83. Apperley, J. F.; Gardembas, M.; Melo, J. V.; Russell-Jones, R.; Bain, B. J.; Baxter, E. J.; Chase, A.; Chessells, J. M.; Colombat, M.; Dearden, C. E.; Dimitrijevic, S.; Mahon, F. X.; Marin, D.; Nikolova, Z.; Olavarria, E.; Silberman, S.; Schultheis, B.; Cross, N. C.; Goldman, J. M. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N. Engl. J. Med. 2002, 347 (7), 481-487.
84. Maki, R. G.; Awan, R. A.; Dixon, R. H.; Jhanwar, S.; Antonescu, C. R. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int. J. Cancer 2002, 100 (6), 623-626.
85. Rubin, B. P.; Schuetze, S. M.; Eary, J. F.; Norwood, T. H.; Mirza, S.; Conrad, E. U.; Bruckner, J. D. Molecular targeting of platelet- derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J. Clin. Oncol. 2002, 20 (17), 3586-3591. [see Comment].
86. Baccarani, M.; Cilloni, D.; Rondoni, M.; Ottaviani, E.; Messa, F.; Merante, S.; Tiribelli, M.; Buccisano, F.; Testoni, N.; Gottardi, E.; de Vivo, A.; Giugliano, E.; Iacobucci, I.; Paolini, S.; Soverini, S.; Rosti, G.; Rancati, F.; Astolfi, C.; Pane, F.; Saglio, G.; Martinelli, G. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica 2007, 92 (9), 1173-1179. [see Comment].
87. Jovanovic, J. V.; Score, J.; Waghorn, K.; Cilloni, D.; Gottardi, E.; Metzgeroth, G.; Erben, P.; Popp, H.; Walz, C.; Hochhaus, A.; Roche- Lestienne, C.; Preudhomme, C.; Solomon, E.; Apperley, J.; Rondoni, M.; Ottaviani, E.; Martinelli, G.; Brito-Babapulle, F.; Saglio, G.; Hehlmann, R.; Cross, N. C.; Reiter, A.; Grimwade, D. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 2007, 109 (11), 4635-4640.
88. Antoniu, S. A. Imatinib mesylate for the treatment of hypereosino-philic syndromes. Curr. Opin. Invest. Drugs 2006, 7 (11), 980-984.
89. Cortes, J.; Ault, P.; Koller, C.; Thomas, D.; Ferrajoli, A.; Wierda, W.; Rios, M. B.; Letvak, L.; Kaled, E. S.; Kantarjian, H. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood 2003, 101 (12), 4714-4716.
90. Pardanani, A.; Reeder, T.; Porrata, L. F.; Li, C. Y.; Tazelaar, H. D.; Baxter, E. J.; Witzig, T. E.; Cross, N. C.; Tefferi, A. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood 2003, 101 (9), 3391-3397. [see Comment].
91. Ault, P.; Cortes, J.; Koller, C.; Kaled, E. S.; Kantarjian, H. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leukemia Res. 2002, 26 (9), 881-884.
92. Gleich, G. J.; Leiferman, K. M.; Pardanani, A.; Tefferi, A.; Butterfield, J. H. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 2002, 359 (9317), 1577-1578.
93. Cools, J.; DeAngelo, D. J.; Gotlib, J.; Stover, E. H.; Legare, R. D.; Cortes, J.; Kutok, J.; Clark, J.; Galinsky, I.; Griffin, J. D.; Cross, N. C.; Tefferi, A.; Malone, J.; Alam, R.; Schrier, S. L.; Schmid, J.; Rose, M.; Vandenberghe, P.; Verhoef, G.; Boogaerts, M.; Wlodarska, I.; Kantarjian, H.; Marynen, P.; Coutre, S. E.; Stone, R.; Gilliland, D. G. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 2003, 348 (13), 1201-1214. [see Comment].
94. Hynes, N. E.; Lane, H. A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 2005, 5 (5), 341-354.
95. Dowell, J. E.; Minna, J. D. Chasing mutations in the epidermal growth factor in lung cancer. New Engl. J. Med. 2007, 352, 830-832.
96. Pao, W.; Politi, K. A.; Reily, G. I.; Somwar, R.; Zakowski, M. F.; Kris, M. G.; Varmus, H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005, 2 (3), e73.
97. Kwak, E. L.; Sordella, R.; Bell, D. W.; Godin-Heymann, N.; Okimoto, R. A.; Brannigan, B. W.; Harris, P. L.; Driscoll, D. R.; Fidias, P.; Lynch, T. J.; Rabindran, S. K.; McGinnis, J. P.; Wissner, A.; Sharma, S. V.; Isselbacher, K. J.; Settleman, J.; Haber, D. A. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc. Nat. Acad. Sci. U.S.A. 2005, 102, 7665-7670.
98. Kumar, A.; Petri, E. T.; Halmos, B.; Boggon, T. J. Structure and clinical relevance fo the epidermal growth factor receptor in human cancer. J. Clin. Oncol. 2008, 26 (10), 1742-1751.
99. Stamos, J.; Sliwkowski, M. X.; Eigenbrot, C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 2002, 277 (48), 46265-46272.
100. Michalczyk, A.; Kluter, S.; Rode, H. B.; Simard, J. R.; Grutter, C.; Baviller, M.; Rauh, D. Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR. Bioorg. Med. Chem. 2008, 16 (7), 3482-3488.
101. Wissner, A.; Mansour, T. S. The development of HKI-272 and related compounds for the treatment of cancer. Arch. Pharm. Chem. Life Sci. 2008, 341, 465-477.
102. Wong, K.-K. HKI-272 in non-small cell lung cancer. Clin. Cancer Res. 2007, 13, 4593-4596.
103. Denny, W. A. Irreversible inhibitors of the erbB family of protein tyrosine kinases. Pharmacol. Ther. 2002, 93, 253-261.
104. Bridges, A. J. The rationale and strategy used to develop a series of highly potent, irreversible, inhibitors of the epidermal growth factor receptor family of tyrosine kinases. Curr. Top. Med. Chem. 1999, 6, 825-843.
105. Wissner, A.; Berger, D. M.; Boschelli, D. H.; Floyd, M. B. J.; Greenberger, L. M.; Gruber, B. C.; Johnson, B. D.; Mamuya, N.; Nilakantan, R.; Reich, M. F.; Shen, R.; Tsou, H.-R.; Upeslacis, E.; Wang, Y.-F.; Wu, B.; Ye, F.; Zhang, N. 4-Anilino-6,7-dialkox-yquinoline-3-carbonitrile inhibitors of epidermal growth factor receptor (EGF-R) kinase and their bioisosteric relationship to the 4-anilino- 6,7-dialkoxyquinazoline inhibitors. J. Med. Chem. 2000, 43, 3244-3256.
106. Li, D.; Ambrogio, L.; Shimamura, T.; Kubo, S.; Takahashi, M.; Chirieac, L. R.; Padera, R. G.; Shapiro, G. I.; Baum, A.; Himmels- bach, F.; Rettig, W. J.; Meyerson, M.; Solca, M.; Greulich, H.; Wong, K.-K. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008, 27 (34), 4702-4711.
107. Yun, C.-H.; Mengwasser, K. E.; Toms, A. V.; Woo, M. S.; Greulich, H.; Wong, K.-K.; Meyerson, M.; Eck, M. J. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc. Natl. Acad. Sci. U.S.A. 2008, 105 (6), 2070-2075.
108. Gray, N. S. Chemical Approaches for Making "Inactive- Conformation" Kinase Inhibitors. Presented at the 236th National Meeting of the American Chemical Society, Philadelphia, PA, 2008.
109. Gajiwala, K. S.; Wu, J.; Lunney, E.; Demetri, G. Novel Mechanisms of Drug Resistance in KIT Mutants from Patients with Gastrointestinal Stromal Tumors: Structural Biology of Wild-Type and Mutated Proteins. Presented at the 236th National Meeting of the American Chemical Society, Philadelphia, PA, 2008.
110. Zunder, E. R.; Knight, Z. A.; Houseman, B. T.; Apsel, B.; Shokat, K. M. Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110alpha. Cancer Cell 2008, 14, 180-192.
111. Azam, M.; Latek, R. R.; Daley, G. Q. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-A-BL. Cell 2003, 112, 831-843.
112. von Bubnoff, N.; Veach, D. R.; van der Kuip, H.; Aulitzky, W. E.; Sander, J.; Seipel, P.; Bornmann, W. G.; Peschel, C.; Clarkson, B.; Duyster, J. A cell-based screeen for resistance of Bcr-Abl-positive leukemia identieifs the mutation pattern for PD166326, an alternative Abl kinase inhibitor. Blood 2005, 105, 1652-1659.
113. Girdler, F.; Sessa, F.; Patercoli, S.; Villa, F.; Musacchoi, A.; Taylor, S. Molecular basis of drug resistance in Aurora kinases. Chem. Biol. 2008, 15 (6), 552-562.
114. Wan, P. T. C.; Garnett, M. J.; Roe, S. M.; Lee, S.; Niculescu-Duvaz, D.; Good, V. M.; Project, C. G.; Jones, C. M.; Marshall, C. J.; Springer, C. J.; Barford, D.; Marais, R. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of b-Raf. Cell 2004, 116, 855-867.
115. Davies, H.; Bignell, G. R.; Cox, C.; Stephens, P.; Edkins, S.; Clegg, S.; Teague, J.; Woffendin, H.; Garnett, M. J.; Bottomley, W.; Davis, N.; Dicks, E.; Ewing, R.; Floyd, Y.; Gray, K.; Hall, S.; Hawes, R.; Hughes, J.; Kosmidou, V.; Menzies, A.; Mould, C.; Parker, A.; Stevens, C.; Watt, S.; Hooper, S.; Wilson, R.; Jayatilake, H.; Gusterson, B. A.; Cooper, C.; Shipley, J.; Hargrave, D.; Pritchard-Jones, K.; Mailtland, N.; Chenevix-Trench, G.; Riggins, G. J.; Bigner, D. D.; Palmieri, G.; Cossu, A.; Flanagan, A.; Nicholson, A.; Ho, J. W. C.; Leung, S. Y.; Yuen, S. T.; Weber, B. L.; Seigler, H. F.; Darrow, T. L.; Paterson, H.; Marais, R.; Marshall, C. J.; Wooster, R.; Stratton, M. R.; Futreal, P. A. Mutations of the BRAF gene in human cancer. Nature 2002, 417, 949-954.